Welcome to the e-CCO Library!

P561: Impact of ustekinumab TDM on clinical practice: a multi-centre, prospective, cross-sectional observational trial—mUST-Decide
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Bressler*1, D. Dajnowiec2, M. Williamson3, K. Karra3, G. Long-Long4, B. Sattin3, W. Afif5

Created: Friday, 22 February 2019, 9:41 AM
P561: Risk of stoma formation in patients with Crohn's perianal fistulas over a two decades period. A cohort study from a tertiary referral center.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bislenghi, G.(1)*;Baldi, C.(1);Ferrante, M.(2);Sabino, J.(2);Verstockt, B.(2);Wolthuis, A.(1);Vermeire, S.(2);D'Hoore, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P561: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo Endoscopic Score (MES) in predicting the therapeutic effect of mesalazine in UC patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: Wu, L.(1);Zhang, Y.(1);Cao, Q.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P562 5-ASA in ulcerative colitis: Are they really needed in the biological therapy era?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Arieira1,2,3, F. Dias de Castro1,2,3, T. Cúrdia Gonçalves1,2,3, M.J. Moreira1,2,3, J. Cotter1,2,3

Created: Thursday, 30 January 2020, 10:12 AM
P562: A Phase 1 Study Evaluating the Effect of Coadministration of Etrasimod on the Pharmacokinetics and Pharmacodynamics of a Monophasic Oral Contraceptive in Healthy Female Volunteers
Year: 2022
Source: ECCO'22
Authors: Lee, C.(1);Tang , Y.(1);Villa-Caballero, L.(2);Liu , K.(3);Randle , A.(4);Grundy , J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P562: Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary center
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cohen, N.A.(1)*;Choi, D.(1);Garcia, N.(1);Choi, N.(1);Picker, E.(1);Krugliak-Cleveland, N.(1);Cohen, R.(1);Dalal, S.(1);Sakuraba, A.(1);Pekow, J.(1);Rubin, D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P562: Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lobaton T.*1, Cañete F.1, Teniente A.2, Cabre E.1,3, Mañosa M.1, Martínez E.2, Domènech E.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P562: Role, efficacy and safety of budesonide multi-matrix in ulcerative colitis in real life: A study in three Italian third-level centres
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Landi1*, N. Mezzina2, S. Carmagnola2, M. Bosani3, E. Filippi4, L. Pastorelli4, S. Grillo1, A. Massari2, A. Cassinotti2, P. Moulteni2, A. Dell'Era2, S. Ardizzone2, G. Maconi2

Created: Thursday, 21 February 2019, 9:14 AM
P562: Treatment of older inflammatory bowel disease patients; steroid use and escalation to steroid sparing therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Asscher*1, N. Provoost1, L. Meijer1, A. van der Meulen-de Jong1, F. van Deudekom2, S. Mooijaart2,3, J. Maljaars1

Created: Friday, 22 February 2019, 9:41 AM
P562: Web-based questionnaire survey about self-management for patients with Inflammatory Bowel Disease in Japan
Year: 2021
Source: ECCO'21 Virtual
Authors: Nagahori, M.(1);Imai, T.(2);Tairaka, A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P563 Shared decision-making in pregnancy in inflammatory bowel disease: Design of a pregnancy in IBD decision aid (PIDA)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.J. Williams1, Y. Leung2, K. O’Connor3, V. Huang3

Created: Thursday, 30 January 2020, 10:12 AM
P563: Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
Year: 2022
Source: ECCO'22
Authors: Rubin, D.T.(1);Torres, J.(2);Regueiro, M.(3);Reinisch, W.(4);Prideaux, L.(5);Kotze, P.G.(6);Tan, F.H.(7);Gardiner, S.(8);Mundayat, R.(8);Cadatal, M.J.(9);Ng, S.(10);
Created: Friday, 11 February 2022, 3:56 PM
P563: Comparison of long-term outcomes of infliximab with adalimumab in biologic naïve patients with Crohn’s disease: a tertiary referral center 13-year experience.
Year: 2021
Source: ECCO'21 Virtual
Authors: Yuksel, I.(1,2);Durak, M.B.(2);Kilic, V.(2);Kivrakoglu, F.(1,2);Kosar, K.(2);Erdogan, C.(2);Alkan, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P563: Monitoring of vedolizumab drug levels in a treat to target strategy for moderate-severe IBD (MOVE-IBD)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Logan, H.(1)*;Rimmer, K.(1);Doecke, J.(2);Patrick, D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P563: Psychotherapy experience and demand for it and their association in inflammatory bowel disease – results from an internet-based survey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Klag T.*1, Mazurak N.2, Fantasia L.1, Schwille-Kiuntke J.2, Kirschniak A.3, Goetz M.1, Malek N.1, Enck P.2, Wehkamp J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P563: Stopping anti-TNFα monotherapy in Crohn's disease patients in deep remission and favourable disease characteristics is associated with a high rate of relapse
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Soufleris1*, N. Kafalis1, K. Fasoulas1, G. Lazaraki1, I. Pilpilidis1, D. Tzilves1, O. Giouleme2

Created: Thursday, 21 February 2019, 9:14 AM
P563: Thiopurine adverse events in patients with inflammatory bowel disease in the UK: inflammatory bowel disease BioResource cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Y. Y. Hong*1, D. A. Withanachchi1, S. P. Aslam1, Y. Khalid1, R. Shawky1, M. Parkes1

Created: Friday, 22 February 2019, 9:41 AM
P564 Psychological acceptance of surgery in patients with inflammatory bowel disease undergoing intestinal resection
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Hirano1,2, M. Itabashi3, T. Saito4, K. Uchida5, M. Inoue5, A. Katsuhiro2, H. Atsuhiro1, K. Araki1, Y. Nishikawa1, M. Tatsuno1, K. Hideaki1, K. Reiko1

Created: Thursday, 30 January 2020, 10:12 AM
P564: A qualitative exploration of acceptability of long-term use of oral nutritional supplement drinks as partial enteral nutrition in adolescent and adult Crohn's Disease
Year: 2022
Source: ECCO'22
Authors: Mu, S.(1);Wei, Y.(1);Weekes, E.(2);Keetarut, K.(2);
Created: Friday, 11 February 2022, 3:56 PM
P564: Indigo naturalis induces mucosal healing in patients with ulcerative colitis: A multicentre randomised controlled trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Naganuma1*, S. Sugimoto1, K. Mitsuyama2, T. Kobayashi3, N. Yoshimura4, H. Ohi5, K. Matsuoka6, T. Hisamatsu7, K. Watanabe8, T. Abe9, M. Watanabe6, T. Hibi3, Y. Suzuki10, T. Kanai1, INDIGO study group

Created: Thursday, 21 February 2019, 9:14 AM